Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 24.69 USD 1.94% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Denali Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Denali Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Net Income (Common)
-$427.5m
CAGR 3-Years
N/A
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Denali Therapeutics Inc
Glance View

Market Cap
3.6B USD
Industry
Biotechnology

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 380 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.

DNLI Intrinsic Value
16.81 USD
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Denali Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-427.5m USD

Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's Net Income (Common) amounts to -427.5m USD.

What is Denali Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-45%

Over the last year, the Net Income (Common) growth was -243%.

Back to Top